Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up
FDA Setback Triggers Strategic Review Kezar Life Sciences revealed a major regulatory setback for its lead drug and immediately pivoted to consider strategic alternatives. In an October 16 press release, the South